本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑 $ q( F% b) r+ b: I9 \: ^
- y4 _. d: S! \clinicaltrials上的三期临床链接# X: j2 z' q4 W2 R+ S9 E2 M
: Z2 T( q9 D; B# o
http://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn* @; @, O1 m; j& t. F& ]3 N
0 n# K: i) n, B4 o$ |, l
中国参加临床实验的城市6 V0 L {- {; u; ?: m
1 ^5 o! T; j C, {9 {" \: z4 DChina, Guangdong ' M- j. f6 e! v; a( e. M
% O+ G5 c2 Q% X4 v x5 D; F" m" ]Guangzhou, Guangdong, China, 510515
3 C0 p% ]$ e( ]9 t$ `, M. D3 B
8 R1 n. X( v8 W( O1 z% i; `Guangzhou, Guangdong, China, 510060 8 p1 A. d2 x# N
China, Jiangsu + E) [3 x1 ~6 @- N+ F' D
! o; x" A% S4 a) k
Nanjing, Jiangsu, China, 210009 / [! C s( Q+ P9 c! h; B$ \
0 f1 G1 G& }( m3 f9 \# T1 LNanjing, Jiangsu, China, 210002 % ?$ E% C: \( c, T/ Q7 F' r
China, Shandong 5 p# k6 _* |8 P2 @' q$ m4 E; E1 `* L
8 R- _5 a0 @/ t. L) SQingdao, Shandong, China, 266003
, j/ ~: o) @4 @3 G! U) uChina
# ?1 g+ j/ t! ?4 ^+ u- C
# ^0 j4 z+ u+ F1 |' q* b0 @Beijing, China, 100021
3 e; Y( g/ l8 c' D% }+ ^ : ^- w6 c; n( _" ?+ W- M
Beijing, China, 100071
0 @$ S5 N2 L% T. x / n5 P0 D* a& B3 V6 D: y( N+ |
Changchun, China, 130021 8 }3 B# S% S$ v' W
2 E7 K( C, w& q+ C' q: Z
Chongqing, China, 400042
% |4 n- w% v2 r6 W / ~' i Z& I, t' I) v0 D
Chongqing, China, 400038 6 j n* s1 ]. d
, K D$ `* x/ D7 fFuzhou, China, 350014 ' x+ J. |" q. \3 c$ S* h
: p! X! Q, D! I, f
Fuzhou, China, 350025 . d% {, E' X y) V$ \0 c: i; z- G
+ u3 P* v5 U2 {! e
Ha'erbin, China, 150040
0 g9 O' W4 Q8 ?. b1 N
$ I8 k" a/ r3 v% x* ^Hanghzou, China, 310009 8 B. c ]4 x/ p# r0 }( n" X) F) P
; R5 y+ G4 f# Q/ ^6 `" C8 T
Shanghai, China, 200001
2 o# l) b' p8 ^
. |1 J5 Q% V# IShanghai, China, 200030
7 U- Y/ \! g1 r! y. ~3 y* U0 x2 Z9 l # Z" D5 ]; X( `( T3 D
Tianjin, China
L# B8 k- L$ C* j3 i7 I% }% K( [5 x G1 ~5 F) d( n( N: U
该实验已停止招募,重新开的临床请见临床专用贴。 |